Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADePT: TGX-007 in High Grade Glioma
NCT07346144Phase 2Recruiting
- Sponsor
- Trogenix
- Start
- Apr 2026
- Primary completion
- Mar 2030
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 2, open-label trial of TGX-007 in glioblastoma (GBM) (3 arms), sponsored by Trogenix. Primary endpoints: Safety and tolerability of TGX-007 and identification of Optimal Biological Dose at 28 days and Overall Survival rate at 18 months. Started Apr 2026; status: recruiting.
02
Drugs
TGX-007
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07346144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346144.